Considering that YAP/TAZ function as the important transcriptional co-regulators in BC development and progression, targeting YAP/TAZ-dependent downstream effectors in a defined context, including metabolic enzymes, kinases, ligands, etc, also represents a very promising therapeutic strategy. Here, YAP1 is linked to breast cancer.